VTRS — Viatris Inc.

The tape and the sell-side disagree, which is why this reads as Neutral rather than Bullish. Constructive inputs: shares are up 22.21% over six months to 2026-09-13, Leerink initiated with Outperform on 2026-09-09, Q2 2026 beat by $0.09 on adjusted EPS with an 8% operational gain in adjusted EBITDA, ~$550m was returned to holders in Q2, and gross leverage came down to 2.9x. Skeptical inputs: the stock is up just 0.18% over three months and fell 2.19% in the week into 2026-09-13, FMP's consensus rating is only 'Hold' (4 buy / 8 hold / 1 sell) with a thin two-analyst price-target sample at $20.50 versus the $18.57-$18.67 cited in the research brief, and trailing GAAP EPS of -$0.353 keeps mechanical value screens from owning it. The market likes the cash story but is not paying up for it.

Revenue troughed at $3.254bn in Q1 2025 (the same quarter as the $2.882bn operating loss) and has since stabilized: $3.582bn -> $3.760bn -> $3.704bn -> $3.517bn -> $3.757bn through Q2 2026. That Q2 2026 print is +4.9% year over year, but still below the $3.797bn booked in Q2 2024, so this is stabilization, not growth - TTM revenue of $14.74bn against next-FY consensus of $14.79bn is essentially zero growth. Gross margin has compressed structurally from ~42-43% in 2023 to 38.8% in Q2 2026 (TTM 34.8%), though Q2 2026's 38.8% was up ~160bp year over year off a messy Q4 2025 (30.6%) and Q1 2026 (32.9%) trough, so the margin trend is now inflecting up rather than down. Reported earnings remain noise: operating income was +$6.3m in Q2 2026 and -$87m TTM despite $1.2bn of quarterly adjusted EBITDA, because amortization of merger intangibles and periodic impairments ($2.882bn in Q1 2025, $265.5m in Q4 2025, $128.2m of Q3 2025 net loss) eat the GAAP line. Free cash flow is the honest metric and it is stable-to-improving: $645.2m (Q3 2025), $550.5m (Q4 2025), $348.4m (Q1 2026), $329.0m (Q2 2026) = $1.873bn TTM, with H1 2026 FCF of $677m ahead of H1 2025's $625m. Balance sheet deleveraging is the clearest structural trend: long-term debt fell from $17.08bn (Q3 2023) to $11.61bn (Q2 2026), though equity also shrank from $20.87bn to $14.26bn on buybacks and impairments, and cash dropped to $886.5m from $1.804bn the prior quarter.

As of 2026-09-13, the honest framing is cheap on cash, not cheap on growth. Forward P/E is 6.58x ($16.51 against next-FY consensus EPS of $2.511), which is at the low end of generic/specialty pharma peers. The trailing P/E of -45.86 and PEG of -3.14 are meaningless artifacts of negative GAAP EPS (-$0.353 TTM). On the cash metrics it looks genuinely inexpensive: TTM FCF of $1.873bn against a $19.2bn market cap is a ~9.7% FCF yield, the dividend yields 2.94%, and the stated EV/EBITDA of 12.1x is computed off depressed GAAP EBITDA - using roughly $4.6bn of FY26 adjusted EBITDA and ~$12.5bn net debt implies closer to ~7x. Offsetting that: P/S of 1.305 is well above the 5-year average of 0.92, so the stock has already re-rated off its lows and is no longer a deep-value sales-based bargain; P/B of 1.347 is not a real asset-backing signal because the $35.0bn asset base is dominated by goodwill and intangibles from the 2020 Mylan/Upjohn combination (equity is $14.26bn against $20.78bn of liabilities); and ROIC of -7.9% with a -0.6% TTM operating margin means the GAAP business earns nothing on capital. Verdict: fair-to-cheap at ~6.6x forward earnings and ~7x adjusted EBITDA, with the discount reflecting real terminal-decline risk rather than pure mispricing.

The interesting feature of VTRS as of 2026-09-13 is that the price is being set off GAAP numbers the business does not actually earn, while the cash numbers the business does earn barely move the multiple. A -$45.86 P/E, -3.14 PEG and -23.9% ROE cause screening systems to reject the name outright, even though Q2 2026 adjusted EPS was $0.69 (an ~$2.76 annualized run-rate) versus -$0.10 GAAP and TTM FCF is $1.87bn. So the market is pricing roughly a melting-ice-cube scenario at 6.6x forward earnings, while simultaneously the +22.2% six-month move shows investors are already partially paying for the deleveraging and the stabilization. The re-rating trigger is not a blowout quarter - it is a narrowing of the GAAP/adjusted gap as merger intangibles amortize down and impairments stop, which would finally make VTRS screen as profitable. Absent that, next-FY EPS estimates actually decline slightly ($2.511) versus the FY26 run-rate, and a 6.6x multiple on flat-to-down earnings is not obviously wrong. Watch the GAAP-to-cash bridge and the top line; the multiple will not fix itself on cost cuts alone.

As of 2026-09-13, RSI(14) was 47.5 - dead neutral, with no oversold or overbought signal. Price was 0.15% below the 20-day SMA (roughly $16.53) and 1.68% below the 50-day (roughly $16.79), but 11.23% above the 200-day (roughly $14.84), which is the textbook picture of a base that has broken out over six months and is now consolidating sideways beneath its 20/50-day averages. Supporting that: +22.21% over six months, but +0.18% over three months and -2.19% over one week, inside a 52-week band of $9.43-$18.39. Entry-timing implication: this is a range, not a trend - there is no urgency to chase, and the stock is not stretched enough to justify waiting for an oversold bounce either. A pullback toward the 200-day near $14.84 would offer a materially better risk/reward for a dividend-and-FCF thesis; a decisive close above the $18.39 52-week high on volume would confirm a new leg higher. Buying at $16.51 in the middle of the range means paying close to fair value for a 'Fair Fundamentals' business.

• US and international drug-pricing pressure: Medicare negotiation, generic volume-based procurement creep, and ongoing mid-single-digit US generic price erosion cap pricing power on Viatris's mature portfolio.
• Higher-for-longer interest rates: with ~$11.6bn of long-term debt on the balance sheet, refinancing costs matter, though gross leverage of 2.9x and three years of paydowns (down from $17.08bn in Q3 2023) blunt the impact; falling rates would be a direct FCF tailwind.
• China healthcare policy: Greater China is a distinct reporting segment and management has pivoted it toward retail and e-commerce to reduce hospital VBP exposure, but policy shifts there remain a live swing factor for reported revenue.
• FX translation: a large share of revenue comes from Emerging Markets and non-US developed markets, so a strong dollar is a recurring reported-revenue headwind (the Q2 2026 '5% reported / 3.5% operational' gap is a reminder).
• Sector rotation and tariffs: healthcare is a defensive destination when growth multiples compress, but pharma-specific tariff/trade and regulatory headlines periodically hit the whole group, and Viatris's generic-manufacturing footprint is tariff-exposed.

• FY2026 guidance delivery and any preliminary FY2027 framing - management raised midpoints across all metrics with Q2 2026, and holding that line is what justifies even a modest multiple re-rate from 6.6x.
• Continued deleveraging and capital returns: roughly $730m remaining on the share repurchase authorization, the $0.12 quarterly dividend (paid 2026-09-16), and further gross debt reduction below the 2.9x leverage level.
• Pipeline readouts and launches - Phase 3 progress for cenerimod (SLE) and selatogrel, plus the US launch ramp for the newly FDA-approved once-weekly contraceptive patch Gwyn Lo.
• Portfolio pruning and bolt-on business development: the up-to-$100m Tyrvaya sale to Harrow shows management will monetize non-core assets, and further divestitures would sharpen the growth profile.
• A narrowing of the GAAP-to-adjusted earnings gap as merger-related intangible amortization steps down and impairment charges stop - the single most plausible trigger for value screens to re-rate the stock.

• Loss of exclusivity and patent cliffs on key mature brands, plus relentless mid-single-digit US generic price erosion - revenue has been flat at ~$14.7bn for three years and next-FY consensus is $14.79bn, i.e. no organic growth engine has yet offset the erosion.
• Chronic GAAP unprofitability driven by non-cash charges: -$0.353 TTM EPS, -0.6% TTM operating margin, -7.9% ROIC, and a -23.9% ROE, with seven of the last twelve quarters showing negative net income. Repeated goodwill write-downs ($2.882bn in Q1 2025 alone) are evidence the 2020 merger's carrying value remains too high.
• Balance-sheet quality: goodwill and intangibles dominate the $35.0bn asset base, so P/B of 1.347 is not real asset backing; a further impairment would cut book value and could pressure credit metrics and the equity story simultaneously.
• Leverage and refinancing: $11.61bn of long-term debt against $886.5m of cash (down from $1.804bn the prior quarter) means the dividend and buyback compete with debt service and bolt-on BD for the same cash flow.
• Policy and geographic concentration risk: US drug pricing reform, Chinese VBP shifts, and pharma tariff/trade actions can hit pricing and volumes with little warning.
• Thin, skeptical sell-side coverage - only two price targets in the FMP dataset and a 'Hold' consensus with one sell rating - means limited institutional sponsorship and a stock that can drift without a narrative refresh.

Viatris is a legitimately cheap cash machine with a mediocre business attached: 6.6x forward earnings, ~9.7% TTM FCF yield, 2.94% dividend, $11.6bn of long-term debt paid down from $17.1bn in three years, and a Q2 2026 that beat with raised guidance. But the reason it trades at 6.6x is that revenue is exactly where it was three years ago ($3.757bn in Q2 2026 versus $3.797bn in Q2 2024), GAAP earnings have been negative in seven of the last twelve quarters, and ROIC of -7.9% says the reported business earns nothing on capital - the cheap multiple is the market discounting a melting ice cube, not mispricing a compounder. At $16.51 on 2026-09-13, in the middle of a $9.43-$18.39 range with RSI at 47.5, I would call this a fair-value income/value holding for a patient investor, not a buy-the-dip moment; the risk/reward improves meaningfully near the 200-day around $14.84 or if new-product and pipeline revenue starts bending the top line up. Not advice - a directional read.

Applied a 7.25x forward P/E to next-FY consensus EPS of $2.511 (versus the 6.58x the 2026-09-13 price of $16.51 implied), a modest re-rating justified by 2.9x gross leverage, a ~9.7% TTM FCF yield ($1.873bn TTM FCF on a $19.2bn market cap), and a 2.94% dividend, but capped by flat revenue and the goodwill/intangibles-heavy balance sheet. Cross-check: 7.25 x $2.511 x ~1.164bn diluted shares = ~$21.2bn equity, plus ~$12.5bn net debt = ~$33.7bn EV, or roughly 7.3x FY26e adjusted EBITDA of ~$4.6bn - consistent with where generic-pharma peers trade on cash earnings.